Variations within proteasome β (PSMB) genes, which encode the β subunits of the 20S
proteasome, may affect proteasome function, assembly, and/or binding of proteasome …

Multiple myeloma (MM) is an incurable disease characterized by clonal expansion of
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …

The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in
the treatment of refractory multiple myeloma. However, its clinical efficacy has been …

We generated eight multiple myeloma cell lines resistant to bortezomib; five acquired
PSMB5 mutations. In 1,500 patients such mutations were rare clinically. To better …

Multiple myeloma (MM) is a hematological malignancy of which complete response (CR) is
rarely achieved by routine chemotherapy. Proteasome inhibitors have been recognized as a …

The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the
chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has marked efficacy …

Purpose: The proteasome is a multisubunit cellular organelle that functions as a
nonlysosomal threonine protease. Proteasomes play a critical role in the degradation of …

Bortezomib (Velcade™) is a reversible proteasome inhibitor that is approved for the
treatment of multiple myeloma (MM). Despite its demonstrated clinical success, some …

The proteasome inhibitor bortezomib has shown impressive clinical activity alone and in
combination with conventional and other novel agents for the treatment of multiple myeloma …

Purpose: Proteasome inhibitors (PI) are the backbone of various treatment regimens in
multiple myeloma. We recently described the first in-patient point mutations affecting the 20S …